Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jul, 2014 | Pages:
146 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Pandemic Influenza - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Pandemic Influenza - Pipeline Review, H2 2014', provides an overview of the Pandemic Influenza's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Pandemic Influenza, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pandemic Influenza and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Pandemic Influenza - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Pandemic Influenza and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Pandemic Influenza products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Pandemic Influenza pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Pandemic Influenza - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Pandemic Influenza pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Pandemic Influenza Overview 8 Therapeutics Development 9 Pipeline Products for Pandemic Influenza - Overview 9 Pipeline Products for Pandemic Influenza - Comparative Analysis 10 Pandemic Influenza - Therapeutics under Development by Companies 11 Pandemic Influenza - Therapeutics under Investigation by Universities/Institutes 15 Pandemic Influenza - Pipeline Products Glance 16 Late Stage Products 16 Clinical Stage Products 17 Early Stage Products 18 Unknown Stage Products 19 Pandemic Influenza - Products under Development by Companies 20 Pandemic Influenza - Products under Investigation by Universities/Institutes 22 Pandemic Influenza - Companies Involved in Therapeutics Development 23 Johnson & Johnson 23 Autoimmune Technologies, LLC 24 GlaxoSmithKline plc 25 MedImmune, LLC 26 Emergent BioSolutions Inc. 27 Lentigen Corporation 28 Takeda Pharmaceutical Company Limited 29 Celltrion, Inc. 30 Novartis AG 31 Novavax, Inc. 32 OPKO Health, Inc. 33 Medicago Inc. 34 BioDiem Ltd 35 TechnoVax, Inc. 36 PDS Biotechnology Corporation 37 Theraclone Sciences, Inc. 38 Sinovac Biotech Ltd. 39 NanoBio Corporation 40 Protein Sciences Corporation 41 Immunovaccine, Inc. 42 VaxInnate Corporation 43 UMN Pharma Inc. 44 Sirnaomics, Inc. 45 AIMM Therapeutics B.V. 46 Cilian AG 47 AmVac AG 48 TSRL, Inc. 49 AltraVax Inc. 50 Big DNA Ltd. 51 ContraFect Corporation 52 PeptiVir, Inc. 53 Pike Pharma GmbH 54 Codagenix, Inc. 55 Pandemic Influenza - Therapeutics Assessment 56 Assessment by Monotherapy Products 56 Assessment by Combination Products 57 Assessment by Target 58 Assessment by Mechanism of Action 60 Assessment by Route of Administration 62 Assessment by Molecule Type 64 Drug Profiles 66 KIB-PCI - Drug Profile 66 Live Attenuated Influenza Vaccine - Drug Profile 67 UMN-0501 - Drug Profile 69 Subunit Vaccine for H5N1 Influenza - Drug Profile 71 TCN-032 - Drug Profile 72 CTP-27 - Drug Profile 74 VX-787 - Drug Profile 75 Pandemic Influenza Vaccine [H5N1] - Drug Profile 76 Pandemic Influenza Vaccine [H7N9] (Monovalent) - Drug Profile 77 MEDI-550 - Drug Profile 79 flu pandemic (H5N1) vaccine - Drug Profile 80 VAX-161 - Drug Profile 81 VAX-16101C - Drug Profile 82 MEDI-9287 - Drug Profile 83 Vaccine for H7N9 Influenza - Drug Profile 84 Flu Vaccine - Drug Profile 85 LG-611 - Drug Profile 86 Subunit Vaccine for H5N1 Pandemic Influenza - Drug Profile 87 STP-702 - Drug Profile 88 TVX-002 - Drug Profile 89 Influenza VLP Vaccine - Drug Profile 90 MVA-H5HA - Drug Profile 91 Flufirvitide-3 - Drug Profile 92 Anti-H5HA mAB - Drug Profile 93 Monoclonal Antibodies to Target Hemagglutinin for Seasonal Influenza and Pandemic Influenza - Drug Profile 94 CF-404 - Drug Profile 95 Pandemic Influenza Vaccine - Drug Profile 96 AMV-411 - Drug Profile 97 CiFlu - Drug Profile 98 Bispecific Monoclonal Antibody for Seasonal and Pandemic Influenza - Drug Profile 100 UMN-0901 - Drug Profile 101 TSR-026 - Drug Profile 102 PDS-0102 - Drug Profile 103 Pandemic Influenza Vaccine - Drug Profile 104 IKT-041 - Drug Profile 105 Pandemic Influenza Vaccine - Drug Profile 106 H7N9 VLP Vaccine + Glucopyranosyl Lipid A Adjuvant - Drug Profile 107 PVI-1000 - Drug Profile 108 A-06 - Drug Profile 109 BDNA-002 - Drug Profile 110 LIAVM-2eHD - Drug Profile 111 Pan-Flu - Drug Profile 113 Pandemic Influenza Vaccine - Drug Profile 114 CTP-25 - Drug Profile 115 Universal Vaccine for Seasonal and Pandemic Influenza - Drug Profile 116 TSR-462 - Drug Profile 117 Monoclonal Antibodies to Inhibit Hemagglutinin for Pandemic Influenza - Drug Profile 118 Small Molecules to Inhibit Viral Polymerase for Influenza - Drug Profile 119 Pandemic Infleunza Vaccine - Drug Profile 120 Vaccine for Pandemic Influenza - Drug Profile 121 Vaccine for Pandemic Influenza - Drug Profile 122 Pandemic Influenza - Recent Pipeline Updates 123 Pandemic Influenza - Dormant Projects 133 Pandemic Influenza - Product Development Milestones 134 Featured News & Press Releases 134 Appendix 141 Methodology 141 Coverage 141 Secondary Research 141 Primary Research 141 Expert Panel Validation 141 Contact Us 142 Disclaimer 142
List of Tables Number of Products under Development for Pandemic Influenza, H2 2014 13 Number of Products under Development for Pandemic Influenza - Comparative Analysis, H2 2014 14 Number of Products under Development by Companies, H2 2014 16 Number of Products under Development by Companies, H2 2014 (Contd..1) 17 Number of Products under Development by Companies, H2 2014 (Contd..2) 18 Number of Products under Investigation by Universities/Institutes, H2 2014 19 Comparative Analysis by Late Stage Development, H2 2014 20 Comparative Analysis by Clinical Stage Development, H2 2014 21 Comparative Analysis by Early Stage Development, H2 2014 22 Comparative Analysis by Unknown Stage Development, H2 2014 23 Products under Development by Companies, H2 2014 24 Products under Development by Companies, H2 2014 (Contd..1) 25 Products under Investigation by Universities/Institutes, H2 2014 26 Pandemic Influenza - Pipeline by Johnson & Johnson, H2 2014 27 Pandemic Influenza - Pipeline by Autoimmune Technologies, LLC, H2 2014 28 Pandemic Influenza - Pipeline by GlaxoSmithKline plc, H2 2014 29 Pandemic Influenza - Pipeline by MedImmune, LLC, H2 2014 30 Pandemic Influenza - Pipeline by Emergent BioSolutions Inc., H2 2014 31 Pandemic Influenza - Pipeline by Lentigen Corporation, H2 2014 32 Pandemic Influenza - Pipeline by Takeda Pharmaceutical Company Limited, H2 2014 33 Pandemic Influenza - Pipeline by Celltrion, Inc., H2 2014 34 Pandemic Influenza - Pipeline by Novartis AG, H2 2014 35 Pandemic Influenza - Pipeline by Novavax, Inc., H2 2014 36 Pandemic Influenza - Pipeline by OPKO Health, Inc., H2 2014 37 Pandemic Influenza - Pipeline by Medicago Inc., H2 2014 38 Pandemic Influenza - Pipeline by BioDiem Ltd, H2 2014 39 Pandemic Influenza - Pipeline by TechnoVax, Inc., H2 2014 40 Pandemic Influenza - Pipeline by PDS Biotechnology Corporation, H2 2014 41 Pandemic Influenza - Pipeline by Theraclone Sciences, Inc., H2 2014 42 Pandemic Influenza - Pipeline by Sinovac Biotech Ltd., H2 2014 43 Pandemic Influenza - Pipeline by NanoBio Corporation, H2 2014 44 Pandemic Influenza - Pipeline by Protein Sciences Corporation, H2 2014 45 Pandemic Influenza - Pipeline by Immunovaccine, Inc., H2 2014 46 Pandemic Influenza - Pipeline by VaxInnate Corporation, H2 2014 47 Pandemic Influenza - Pipeline by UMN Pharma Inc., H2 2014 48 Pandemic Influenza - Pipeline by Sirnaomics, Inc., H2 2014 49 Pandemic Influenza - Pipeline by AIMM Therapeutics B.V., H2 2014 50 Pandemic Influenza - Pipeline by Cilian AG, H2 2014 51 Pandemic Influenza - Pipeline by AmVac AG, H2 2014 52 Pandemic Influenza - Pipeline by TSRL, Inc., H2 2014 53 Pandemic Influenza - Pipeline by AltraVax Inc., H2 2014 54 Pandemic Influenza - Pipeline by Big DNA Ltd., H2 2014 55 Pandemic Influenza - Pipeline by ContraFect Corporation, H2 2014 56 Pandemic Influenza - Pipeline by PeptiVir, Inc., H2 2014 57 Pandemic Influenza - Pipeline by Pike Pharma GmbH, H2 2014 58 Pandemic Influenza - Pipeline by Codagenix, Inc., H2 2014 59 Assessment by Monotherapy Products, H2 2014 60 Assessment by Combination Products, H2 2014 61 Number of Products by Stage and Target, H2 2014 63 Number of Products by Stage and Mechanism of Action, H2 2014 65 Number of Products by Stage and Route of Administration, H2 2014 67 Number of Products by Stage and Molecule Type, H2 2014 69 Pandemic Influenza Therapeutics - Recent Pipeline Updates, H2 2014 127 Pandemic Influenza - Dormant Projects, H2 2014 137
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
